RT Journal Article
SR Electronic
T1 In search for the hotspots of Disease X: A biogeographic approach to mapping the predictive risk of WHO’s Blueprint Priority Diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.27.20044156
DO 10.1101/2020.03.27.20044156
A1 Jagadesh, Soushieta
A1 Combe, Marine
A1 Nacher, Mathieu
A1 Gozlan, Rodolphe Elie
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.27.20044156.abstract
AB Anthropization of natural habitats including climate change along with overpopulation and global travel have been contributing to emerging infectious diseases outbreaks. The recent COVID-19 outbreak in Wuhan, highlights such threats to human health, social stability and global trade and economy. We used species distribution modelling and environmental data from satellite imagery to model Blueprint Priority Diseases occurrences. We constructed classical regression and Support Vector Machine models based on environmental predictor variables such as landscape, tree cover loss, climatic covariates. Models were evaluated and a weighed mean was used to map the predictive risk of disease emergence. We mapped the predictive risk for filovirus, Nipah, Rift Valley Fever and coronavirus diseases. Elevation, tree cover loss and climatic covariates were found to significant factors influencing disease emergence. We also showed the relevance of disease biogeography and in the identification potential hotspots for Disease X in regions in Uganda and China.Article Summary Line In our study with the use of a biogeographic approach, we were able to identify Wuhan as a potential hotspot of disease emergence in the absence of COVID-19 data and we confirm that distribution of disease emergence in humans is spatially dependent on environmental factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSoushieta Jagadesh receives funding from the University of Guyane as part of her ongoing PhD thesis.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript uses public data and the data sources are citated